Our history

Theratechnologies was founded in 1993. Theratechnologies scientists discovered EGRIFTA® (tesamorelin for injection) in 1995. For the next 15 years, Theratechnologies continued to develop this innovative treatment for lipodystrophy in people living with HIV. In 2010, Theratechnologies received a marketing authorization for EGRIFTA® from the US Food and Drug Administration.

Growing our business to become a significant player in the pharma industry by making a difference in the lives of patients with special medical needs.

World EN Placeholder
World EN
World Point EN Placeholder
World Point EN
Our offices
  • Our offices
    Montreal

    Theratechnologies employs 40 people at its head office located at 2015 Peel Street, 11th floor, Montreal, Quebec H3A 1T8.

    Dublin

    Theratechnologies European head office is located in Dublin, Ireland. Around ten people are working at this office located at 2 rue Hume Street, 4th floor, Dublin 2, D02 DV24.

  • Covered Territories
    Canada
    United States
    Mexico
    Denmark
    Estonia
    Finland
    United Kingdom
    Ireland
    Lithuania
    Latvia
    Sweden
    Austria
    Belgium
    Germany
    France
    Liechtenstein
    Luxembourg
    Monaco
    Netherlands
    Bulgaria
    Czechia
    Hungary
    Poland
    Romania
    Slovakia
    Albania
    Spain
    Gibraltar
    Greece
    Croatia
    Italy
    Malta
    Portugal
    Slovenia
    Cyprus
    Greece

Theratechnologies around the world

Theratechnologies operates in Canada, the United States and Europe.

Our mission

As a caring partner of choice, bring to market specialized therapies to support the healthcare community in making lives better for people with orphan medical conditions, including those living with HIV.

Our values

Agility

The Company operates in a highly competitive and regulated field. We must constantly be creative and resourceful in finding innovative solutions that enable the Company to make the right decisions in a timely manner.

Tenacity

There are many challenges in our field. Theratechnologies' employees do not shy away from a challenge and demonstrate resilience, drive and determination in finding innovative solutions and achieving the Company's goals.

Commitment

We are fully committed to market innovative therapies for orphan medical conditions. Our commitment also translates to our shareholders by continuously ensuring the growth of the Company.

Our History

Theratechnologies was founded in 1993.

Theratechnologies was founded in 1993. Scientists at Theratechnologies discovered EGRIFTA®(tesamorelin for injection) in 1995. For the next fifteen years, Theratechnologies pursued the development of this innovative treatment for lipodystrophy in people living with HIV. In 2010, Theratechnologies received a marketing authorization for EGRIFTA® from the Food and Drug Administration in the United States.

 

EGRIFTA® was first marketed by a third-party commercial partner in the United States. Then, in 2014, Theratechnologies made a strategic decision and reoriented its business model to become a commercial-stage biopharmaceutical company. This is when Theratechnologies regained commercial rights to EGRIFTA® in the United States.

 

This move gave Theratechnologies the means to look at other acquisitions which came shortly thereafter. The Company concluded an agreement to acquire the commercial rights to Trogarzo® in the United States, Europe, Canada, the Scandinavian countries, Russia, Israel and Switzerland. Trogarzo® was approved by the FDA in 2018 and was quickly adopted by hundreds of physicians to treat people living with HIV.

 

Trogarzo® was recently approved in Europe where it will be commercialized very soon but already several patients are being treated through various early access programs funded by local governments.

 

Theratechnologies is already looking beyond and working on the lifecycle of its commercialized products.

 

The Company announced its intention to develop tesamorelin, the active ingredient in EGRIFTA®, for the treatment of Non-Alcoholic Steatohepatitis (NASH) in people living with HIV.

 

Furthermore, new delivery methods are being investigated for Trogarzo® to make it even more patient friendly.

 

True to its commitment to provide solutions to unmet medical needs in niche market segments, Theratechnologies is also pursuing the development of a highly targeted oncology platform for various types of cancers.